bluebird bio Inc BLUE
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if BLUE is a good fit for your portfolio.
News
-
ROSEN, A LEADING NATIONAL FIRM, Encourages bluebird bio Inc. Investors to Inquire About Securities Class Action Investigation – BLUE
-
Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against bluebird bio, Inc. (BLUE)
-
BLUE INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that bluebird bio, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!
-
Class Action Filed Against bluebird bio, Inc. (BLUE) - May 28, 2024 Deadline to Join – Contact Levi & Korsinsky
-
SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Blue
-
Class Action Filed Against bluebird bio, Inc. (BLUE) - May 28, 2024 Deadline to Join - Contact The Gross Law Firm
-
SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against bluebird bio, Inc. - BLUE
-
DEADLINE ALERT for EVLV, BLUE, and LUNA: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders
Trading Information
- Previous Close Price
- $0.90
- Day Range
- $0.89–0.94
- 52-Week Range
- $0.86–5.53
- Bid/Ask
- $0.91 / $0.92
- Market Cap
- $173.43 Mil
- Volume/Avg
- 7.1 Mil / 8.3 Mil
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 4.20
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
bluebird bio Inc is a biotechnology company engaged in researching, developing, and commercializing potentially curative gene therapies for severe genetic diseases based on its proprietary lentiviral vector (LVV) gene addition platform. The Company operates in a single segment, focusing on researching, developing and commercializing potentially transformative gene therapies for severe genetic diseases.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Core
- Total Number of Employees
- 323
- Website
- https://www.bluebirdbio.com
Comparables
Valuation
Metric
|
BLUE
|
FDMT
|
SWTX
|
---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 0.43 | 3.69 | 5.89 |
Price/Sales | 4.20 | 49.81 | 112.52 |
Price/Cash Flow | — | — | — |
Price/Earnings
BLUE
FDMT
SWTX
Financial Strength
Metric
|
BLUE
|
FDMT
|
SWTX
|
---|---|---|---|
Quick Ratio | 1.24 | 15.21 | 6.21 |
Current Ratio | 1.55 | 15.65 | 6.41 |
Interest Coverage | — | — | — |
Quick Ratio
BLUE
FDMT
SWTX
Profitability
Metric
|
BLUE
|
FDMT
|
SWTX
|
---|---|---|---|
Return on Assets (Normalized) | −12.29% | −25.94% | −40.43% |
Return on Equity (Normalized) | −30.63% | −28.64% | −46.62% |
Return on Invested Capital (Normalized) | −15.27% | −31.25% | −50.77% |
Return on Assets
BLUE
FDMT
SWTX
Biotechnology Industry Comparables
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Fffxkzmk | Lcv | $545.9 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Hpdfhyk | Kwcdj | $105.4 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Tzkslhwd | Gblrwt | $103.7 Bil | |
MRNA
| Moderna Inc | Nfhmhtzct | Rbg | $47.9 Bil | |
ARGX
| argenx SE ADR | Zlvwxvrx | Zmskm | $22.9 Bil | |
BNTX
| BioNTech SE ADR | Zykvswyz | Hqx | $22.3 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Xrgzgvr | Gcfzvx | $19.3 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Mrqsfsmz | Ypbhb | $15.7 Bil | |
RPRX
| Royalty Pharma PLC Class A | Clbxdkkrx | Yrxhgjf | $12.8 Bil | |
INCY
| Incyte Corp | Zzjswjjyd | Fpbrvzq | $12.1 Bil |